Recursion Pharmaceuticals Inc (RXRX) stock news · rev $74.7M
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
This RXRX news page leads with what Recursion Pharmaceuticals Inc filed — not a scraped headline mill.
No cached 8-K sentence for RXRX yet. We will not pad this page with generic market recap.
Latest reported RXRX revenue for 2025-12-31 was $74.7M. Net income was -$644.8M. Revenue was up 26.9% from 2024-12-31 to 2025-12-31. RXRX currently screens at market cap $1.75B.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the RXRX stock page; for the tape open the quote page.
RXRX stock news FAQ
What are RXRX's latest revenue and net income?
Latest cached Recursion Pharmaceuticals Inc (RXRX) revenue for Dec 31, 2025 was $74.7M. Net income was -$644.8M. Statements: https://lician.com/financials/rxrx
How did RXRX revenue change from the prior cached period?
Cached Recursion Pharmaceuticals Inc (RXRX) revenue was up 26.9% from $58.8M (Dec 31, 2024) to $74.7M (Dec 31, 2025). Statements: https://lician.com/financials/rxrx
What is RXRX's market cap?
Recursion Pharmaceuticals Inc (RXRX) market cap is $1.75B on the latest cached fundamentals snapshot.
What kind of company is RXRX?
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Where is RXRX stock news listed?
Cached stock news for Recursion Pharmaceuticals Inc (RXRX) is listed at https://lician.com/news/rxrx. Filings: https://lician.com/sec/rxrx
Not investment advice.